Islamabad: Budding friendhip between Pakistan and China! Pakistan PM Nawaz Sharif on Monday inaugurated the Pakistan-China Friendship Tunnels, which have been constructed by China overlooking the Attabad Lake in Gilgit-Baltistan.
The seven-kilometre-long five tunnels are part of the 24-km portion of the Karakoram Highway (KKH) which was damaged in 2010 due to land slides at Attabad.
Two major bridges and 78 small bridges have also been constructed on the rebuilt section of the highway, reported Radio Pakistan.
The tunnels have been constructed by the National Highway Authority (NHA) in collaboration with the China Road and Bridge Corporation to restore part of the road which had become submerged under the Attabad lake waters.
The project has been completed in a span of three years and two months.
China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.
Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.
A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.
An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.
China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.
Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.
Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.